We offer a specialized service based on a unique human whole-blood loop assay, that uses fresh, circulating blood with all components present, including cascade systems. Alternative assays lack one or more of the blood components such as active complement, neutrophils, erythrocytes, platelets, endogenous immunoglobulins or plasma proteins, which makes our assay truly an exclusive tool for advanced characterization of biotherapeutics.
The whole-blood loop assay can be used for detection of immune-related side effects of biopharmaceuticals (cytokine release), which provides a better understanding of first-in-man reactions prior to clinical trial entry. Our customized services are paired with our immunological know-how and expertise, enabling us to enhance data output, optimally support your drug development process and improve your clinical trial design.
Are you interested in using our whole-blood loop model to assess toxicity or/and efficacy of your drug candidate? Contact us to find out how we can help you!
Join us at EuropeanAntibody Congress that takes place in Congress Centre, Basel, Switzerland,29-31 October 2018.
The Norwegian biotech company Ultimovacs AS took over the immunotherapy technology business of the Swedish company Immuneed AB last month. The complementary technologies of the two companies provide a unique platform for development of novel vaccine solutions for treatment and possibly prevention of cancer.